ITM Pharma Solutions

ITM Isotope Technologies Munich is a leading privately held radiopharmaceutical company dedicated to the development, production, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals for oncology. The company leverages its proprietary platform and extensive manufacturing infrastructure to produce high-purity medical isotopes, such as no-carrier-added Lutetium-177, which serve as the foundation for its internal pipeline and for partners worldwide. ITM's lead therapeutic candidate, ITM-11, is currently in Phase 3 clinical development for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). By combining precise targeting molecules with powerful radioisotopes, ITM aims to provide more effective and less toxic treatment options for patients with hard-to-treat cancers. The company maintains a significant global distribution network, supporting the growing field of precision oncology and Targeted Radionuclide Therapy.